All the news Showing 10 of 204 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Medicines Excitement in the Netherlands – New Health Minister announces firm action on “absurd” medicines pricing Medicines Law & Policy / 27 November 2017 ‘Think outside the box’ to finance HCV elimination Healio / 22 November 2017 Eliminating viral hepatitis: time to match visions with action The Lancet (editorial) / 10 November 2017 MSF secures generic hepatitis C treatment at $120 compared to $147,000 launch price tag MSF press release / 31 October 2017 UK pharma denied legal challenge to drugs bill cap Pharmaphorum / 05 October 2017 Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment Kaiser Health News / 05 October 2017 High prices of DAAs mean there's been little progress towards achieving WHO target of eliminating HCV by 2030 Michael Carter / 13 September 2017 Only a handful of countries are on course to achieve the World Health Organization (WHO) target of eliminating hepatitis C virus (HCV) as a major public health concern by 2030, ... AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance Bloomberg / 07 August 2017 Reining in Drug Prices: Easier Said than Done MedPage Today / 02 August 2017 Hepatitis C patients unable to get drugs due to funding problems Irish Times / 31 July 2017 ← Prev12345...21Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive